Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

January 30, 2025

Study Completion Date

June 30, 2025

Conditions
Head and Neck Squamous Cell CarcinomaRadiotherapyRadiosensitizerPirfenidone
Interventions
DRUG

Pirfenidone

Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.

DRUG

Placebo

Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.

Trial Locations (5)

510515

RECRUITING

Southern medical university, Guangzhou

Unknown

NOT_YET_RECRUITING

Fujian Provinical Hospital, Fuzhou

NOT_YET_RECRUITING

Huizhou Central People's Hospital, Huizhou

NOT_YET_RECRUITING

Jieyang people's hospital, Jieyang

NOT_YET_RECRUITING

Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou, Meizhou

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT06142318 - Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter